Skip to main content
. 2022 Jun 28;25(5):366–378. doi: 10.4048/jbc.2022.25.e30

Figure 3. MP-guided treatment. (A) Targetable genomic alterations (n = 81) in locally patients with advanced/metastatic breast cancer (n = 127). (B) Composition of targetable genomic alterations of SNVs/indels. (C) Types of MP-guided treatment in patients with advanced breast cancer with targetable genomic alterations. (D) Access to MP-guided treatment.

Figure 3

MP, molecular profiling; NHS, National Health Insurance Service; EAP, expanded access program; SNV, single-nucleotide variant; indel, insertion or deletion; MSI-H, microsatellite instability-high; HER, human epidermal growth factor receptor.